I don't think the impact is that drastic (and I don't think the buyout price was ever going to be that high).
Sales keep going up, in any case, and the decision should come back this year. What did it cost in the end? Maybe a few bucks a share. At this point that feels like a rounding error.
Retire. assuming we win the patent appeal .. and in my non professional opinion Singer puts forth a very convincing argument ...there is new clinical data to drive sales of Vascepa ...whenever Amarin wish to more actively promote . Specifically the lower rate of revasculareization ...study recently published ....and then hopefully "robust " findings from the final results of the EVAPORATE trial ....due later this year . ( correct if wrong please )
The impacts of COVID ( fewer MD office visits etc ) is IMHO probably eating up more of the patent life valuation than this legal challenge .
Yes, they're worth less in a BO now because of the lost years of R-IT DTC ads and sales - but how do you figure the loss of $5B-$7B in sales would take double off the BO valuation (AMRN worth $7B-$10B less)? Those numbers are way too high in any case - AMRN may have only lost an extra $500M in sales due to this, and even that's questionable because FDA approval came so late last year V didn't get bumped up a tier on Medicare Part D 2020 plan formularies, and those sales won't show up until 2021.
News 
Market Data 
Discover 
